ADAP Quote, Financials, Valuation and Earnings

Bicycle Therapeutics PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -1398.44%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Bicycle Therapeutics PLC's return on equity of -26.21%.

Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 196.05%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.

Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.

Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus 16.46x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 753.38%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus 1.91x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

TC BioPharm (Holdings) PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat TC BioPharm (Holdings) PLC's return on equity of --.

Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2642.86%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -92.29%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Verona Pharma PLC's return on equity of -88.7%.

Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 21.7%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.

Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.

Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Verona Pharma PLC quarterly revenues of $36.7M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.